Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (M...

Full description

Saved in:
Bibliographic Details
Published in:Biological psychiatry (1969) 1995-08, Vol.38 (3), p.185-188
Main Authors: Lawlor, Brian A., Bierer, Linda M., Ryan, Theresa M., Schmeidler, James, Knott, Peter J., Williams, Lizette L., Mohs, Richard C., Davis, Kenneth L.
Format: Article
Language:English
Subjects:
Affective Symptoms - diagnosis
Affective Symptoms - physiopathology
Affective Symptoms - psychology
Aged
Aged, 80 and over
Alzheimer Disease - diagnosis
Alzheimer Disease - physiopathology
Alzheimer Disease - psychology
Alzheimer's disease
Biological and medical sciences
clinical symptoms
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Humans
Male
Medical sciences
Methoxyhydroxyphenylglycol - blood
Middle Aged
Neurology
Neuropsychological Tests
Norepinephrine - physiology
plasma MHPG
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), and clinical symptoms was examined in 23 patients with probable AD. Basal MHPG levels correlated significantly with increased cognitive impairment ( r = .58, p = .005), controlling for age, age at onset, gender, and time interval between plasma MHPG determination and cognitive testing. These results suggest that plasma MHPG increases as cognitive function in AD deteriorates, further supporting preliminary evidence for increases in noradrenergic indices in association with disease severity in AD.
ISSN:0006-3223
1873-2402
DOI:10.1016/0006-3223(94)00259-6